
Thermo Fisher Scientific TMO
€ 400.24
-0.02%
Geschäftsbericht 2025
hinzugefügt 26.02.2026
Thermo Fisher Scientific Finanzkreislauf 2011-2026 | TMO
Finanzkreislauf Jährlich Thermo Fisher Scientific
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 70 | 69.8 | 69.6 | 65.4 | 63.9 | 57.2 | 108 | 99.6 | 124 | 116 | 101 | 93.8 | 92.9 | 93.2 | 94.8 |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 124 | 57.2 | 88 |
Finanzkreislauf Vierteljährlich Thermo Fisher Scientific
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 71.8 | 71.7 | 73.6 | 69.7 | 68.7 | 71.9 | 70.7 | 68.1 | 68.3 | - | 32.8 | 32.8 | 61.2 | - | 54 | 54.3 | 52 | - | 61.5 | 75.7 | 73.9 | 58.1 | 63.3 | 62.8 | 63.2 | 58 | 63.8 | 62.1 | 62.5 | 58.5 | 69.2 | 70.9 | 66.3 | 56.2 | 61.9 | 61.3 | 59.4 | 49.9 | 56.3 | 54.4 | 58.4 | 50.2 | 54.1 | 52.2 | 51.6 | 51.1 | 55.5 | 54.7 | 53.6 | 50.5 | 53.4 | 53 | 53.3 | 52.1 | 55.2 | 57.5 | - |
Alle Zahlen in USD-Währung
Indikatorspanne aus vierteljährlicher Berichterstattung
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 75.7 | 32.8 | 59.4 |
Finanzkreislauf anderer Aktien in der Diagnostik & Forschung
| Name | Finanzkreislauf | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
|
Akumin
AKU
|
36.1 | - | -17.87 % | $ 25.9 M | ||
|
Centogene N.V.
CNTG
|
50.2 | - | -6.23 % | $ 30.6 M | ||
|
Agilent Technologies
A
|
111 | $ 114.72 | -0.78 % | $ 34.9 B | ||
|
Co-Diagnostics
CODX
|
-2.46 K | $ 1.6 | -3.03 % | $ 2.13 M | ||
|
Accelerate Diagnostics
AXDX
|
364 | - | -61.36 % | $ 2.46 M | ||
|
Chembio Diagnostics
CEMI
|
111 | - | 0.22 % | $ 16.8 M | ||
|
Aspira Women's Health
AWH
|
1.01 K | - | -6.19 % | $ 10.5 M | ||
|
Biocept
BIOC
|
78.1 | - | -13.05 % | $ 7.29 M | ||
|
Castle Biosciences
CSTL
|
45.9 | $ 24.63 | -1.4 % | $ 684 M | ||
|
Enzo Biochem
ENZ
|
154 | - | -8.98 % | $ 14.8 K | ||
|
CareDx, Inc
CDNA
|
51.5 | $ 22.1 | 1.14 % | $ 1.18 B | ||
|
Precipio
PRPO
|
19.9 | $ 31.07 | 1.19 % | $ 49.9 M | ||
|
Illumina
ILMN
|
142 | $ 126.85 | -1.3 % | $ 20.2 B | ||
|
DermTech
DMTK
|
66.7 | - | -11.32 % | $ 2.94 M | ||
|
Exact Sciences Corporation
EXAS
|
42.5 | - | - | $ 19.8 B | ||
|
Fulgent Genetics
FLGT
|
42.4 | $ 15.24 | -2.31 % | $ 461 M | ||
|
HTG Molecular Diagnostics
HTGM
|
104 | - | -20.0 % | $ 1.06 M | ||
|
Global Cord Blood Corporation
CO
|
184 | - | - | $ 399 M | ||
|
Lantheus Holdings
LNTH
|
97.3 | $ 82.87 | -1.47 % | $ 5.59 B | ||
|
Genetic Technologies Limited
GENE
|
11 K | - | - | $ 7.1 B | ||
|
Genetron Holdings Limited
GTH
|
142 | - | 0.12 % | $ 80.1 M | ||
|
Charles River Laboratories International
CRL
|
65 | $ 166.83 | -2.57 % | $ 8.27 B | ||
|
PRA Health Sciences, Inc.
PRAH
|
1.21 K | - | - | $ 10.7 B | ||
|
National Research Corporation
NRC
|
29.4 | $ 16.9 | -1.23 % | $ 378 M | ||
|
Guardant Health
GH
|
79.6 | $ 82.93 | -6.29 % | $ 10.4 B | ||
|
Heska Corporation
HSKA
|
138 | - | - | $ 1.31 B | ||
|
Koninklijke Philips N.V.
PHG
|
89 | $ 27.08 | -1.67 % | $ 20 B | ||
|
Interpace Biosciences
IDXG
|
62.9 | $ 1.93 | - | $ 8.54 M | ||
|
Personalis
PSNL
|
-11.5 | $ 5.49 | -7.89 % | $ 325 M | ||
|
Senseonics Holdings
SENS
|
36.1 | $ 7.15 | -1.65 % | $ 298 M | ||
|
Medpace Holdings
MEDP
|
50.4 | $ 416.82 | -1.08 % | $ 12 B | ||
|
QIAGEN N.V.
QGEN
|
122 | - | - | $ 10.6 B | ||
|
Motus GI Holdings
MOTS
|
3.45 K | - | -34.28 % | $ 263 K | ||
|
Biomerica
BMRA
|
172 | $ 2.15 | -1.38 % | $ 4.94 M | ||
|
ICON Public Limited Company
ICLR
|
62 | $ 101.08 | -2.07 % | $ 8.34 B | ||
|
Laboratory Corporation of America Holdings
LH
|
40.3 | $ 260.29 | -1.19 % | $ 21.7 B | ||
|
Trinity Biotech plc
TRIB
|
136 | $ 0.62 | -4.08 % | $ 61.9 M | ||
|
Neogen Corporation
NEOG
|
150 | $ 9.12 | -3.54 % | $ 1.98 B | ||
|
Twist Bioscience Corporation
TWST
|
83.6 | $ 59.49 | -2.48 % | $ 3.56 B | ||
|
NeoGenomics
NEO
|
82.4 | $ 8.9 | 3.43 % | $ 1.14 B | ||
|
Myriad Genetics
MYGN
|
49.3 | $ 4.83 | -0.1 % | $ 447 M | ||
|
Natera
NTRA
|
81.5 | $ 200.24 | -2.03 % | $ 19.7 B | ||
|
Quest Diagnostics Incorporated
DGX
|
39.5 | $ 195.7 | -0.47 % | $ 21.7 B | ||
|
Invitae Corporation
NVTA
|
299 | - | - | $ 21.2 M | ||
|
OpGen
OPGN
|
4.66 | - | -16.95 % | $ 1.54 M |